Virscio is a enabling development of advanced medicines through the integration and application of next generation in vivo models, technologies, and preclinical capabilities.
Who We Are
At Virscio, our name reflects our mission: to enhance the human condition through a deeper understanding of human biology.
Our team is passionate about impacting human health. to address major human health challenges. We are at the forefront of reducing translational risks by leveraging the latest insights in human pathophysiology. This knowledge guides us in developing and refining predictive preclinical models that accurately mirror human disease and therapeutic interventions.
Our approach to these complex challenges is defined by unmatched preclinical expertise and capabilities. We offer:
- Expert knowledge across various therapeutic areas.
- Industry-leading efficiency in project initiation and data delivery.
- Customized, hands-on involvement aligned with specific goals.
- A commitment to producing clear, actionable results and conclusions.
- A comprehensive range of proven efficacy and safety models and delivery techniques.
- Ethical and sustainable access to a large, biologically pristine nonhuman primate population.
Our Mission
Virscio stands at the forefront of expediting therapeutic innovation and enhancing R&D efficiency. We achieve this through our development and provision of cutting-edge preclinical models, methods, and technologies. Our comprehensive preclinical research and development capabilities, combined with a unique focus on multidisciplinary nonhuman primate translation and a deep commitment to animal welfare, set us apart globally.
Our mission is driven by three core objectives:
- Time, Cost, and Risk Reduction: We focus on speeding up the selection and development of potential therapeutics, aiming to diminish the time and costs associated with reaching clinical trials. Our approach significantly lowers the risk of clinical failure and potential human harm.
- Application of Optimal Models and Technologies: Our goal is to enhance the prediction of clinical outcomes through the humane and sustainable use of optimized nonhuman primate models and endpoints. This approach ensures the best tools and technologies are applied in biomedical development.
- Fostering Therapeutic Innovation: At Virscio, we are dedicated to pioneering next-generation technologies and services. Our efforts are geared towards boosting research and development productivity and reducing reliance on animal testing.
At Virscio we are not just contributing to biomedical research; we're redefining it by bridging advanced science with ethical practices for a healthier tomorrow.
Our People
At Virscio, we are focused on enabling the next wave of biomedical innovation through a unique combination of unique research resources, scientific creativity, and efficient execution. Our aim is to deliver high value, clinically research that significantly de-risks the path the clinical success.
Meet the Team
Matthew Lawrence, M.D., Ph.D.
Co-Founder, Chief Executive Officer, CSO
Christopher Stanley
Co-founder, Chief Business Officer, CFO
Rob Goody, Ph.D.
Chief Technology Officer
Jeanne Damon
Vice President of People
Calvin Carpenter, DVM
Chief Veterinarian
Ben Culp
Director of Research Operations
Alex Nesbitt
Facility Director
Dr. Sven Korte, Ph.D.
Senior Director of Research and Safety Assessment
Jennifer Cann, Ph.D.
Director of Pathology
Richard Bouffard
Directory of Histology
Bibiana Iglesias, Ph.D.
Associate Director of Ophthalmology
Cavit Agca, Ph.D.
Associate Director of Molecular Biology
Rahul Dange, Ph.D.
Senior Research Pathologist
Michael Weed, Ph.D.
Principal Scientist, CNS
John Elsworth, Ph.D.
Principal Scientist, CNS
Shervin Liddie, Ph.D.
Director of Scientific Execution
Define your development path.
We’re ready to help you optimize your path to clinical success.
